Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048620 · ClinicalTrials.gov registry record · Phase 1
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
A Phase 1 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00048620: Completed Phase 1 study, sponsored by BioMarin Pharmaceutical.
NCT00048620 is a Phase 1 study that has completed, run by BioMarin Pharmaceutical. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048620, a Phase 1 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
Interventions
- DRUG N-acetylgalactosamine 4-sulfatase
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
What the finished NCT00048620 record still lists
NCT00048620 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which N-acetylgalactosamine 4-sulfatase is the first listed.
NCT00048620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00048620 about?
NCT00048620 is a clinical study titled "Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI". The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
What is the current status of trial NCT00048620?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-09. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00048620?
The interventions under investigation include: N-acetylgalactosamine 4-sulfatase (DRUG).
Who is sponsoring clinical trial NCT00048620?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia